Trials / Active Not Recruiting
Active Not RecruitingNCT03618537
Ixazomib Maintenance Study in Patients With AL Amyloidosis
Ixazomib Maintenance Following Initial Therapy in Patients With Immunoglobulin Light Chain (AL) Amyloidosis
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn if Ixazomib maintenance treatment (chemotherapy) works to control the disease. Through this study, the investigators hope to learn more about ways to prevent or delay relapse of AL Amyloidosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixazomib | Ixazomib at a fixed dose of 4mg on days 1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle. |
| DRUG | Dexamethasone | Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue. |
Timeline
- Start date
- 2018-08-02
- Primary completion
- 2026-08-01
- Completion
- 2026-08-01
- First posted
- 2018-08-07
- Last updated
- 2025-12-04
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03618537. Inclusion in this directory is not an endorsement.